Recombinant Human Cathepsin D protein (His Tag)
ED50
/
Species
Human
Purity
>90 %, SDS-PAGE
GeneID
1509
Accession
P07339
验证数据展示
Technical Specifications
Purity | >90 %, SDS-PAGE |
Endotoxin Level | <1.0 EU/μg protein, LAL method |
Biological Activity |
Not tested |
Source | HEK293-derived Human Cathepsin D protein Leu21-Leu412 (Accession# P07339) with a His tag at the C-terminus. |
Predicted Molecular Mass | 43.4 kDa |
SDS-PAGE | 43-49 kDa, reducing (R) conditions |
Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CTSD (Cathepsin D), also named CPSD, belongs to the peptidase A1 family. It is ubiquitously expressed and is involved in proteolytic degradation, cell invasion, and apoptosis. Human CTSD is synthesized as a 52-kDa precursor that is converted into an active 48-kDa single-chain intermediate in the endosomes, and then into a fully active mature form, composed of a 34-kDa heavy chain and a 14-kDa light chain, in the lysosomes. It is a lysosomal acid protease found in neutrophils and monocytes and involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease (PMID: 27114232, PMID: 30717773, PMID: 30051532).
References:
1. Vidoni C, et al. (2016). Med Res Rev. 36(5):845-70. 2. Ashraf Y, et al. (2019). J Immunother Cancer. 7(1):29. 3. Chai YL, et al. (2019). Brain Pathol. 29(1):63-74. 4. Mijanovic O, et al. (2021). Pharmaceutics. 5;13(6):837.